Becton Dickinson and Co (NYSE:BDX) Shares Sold by A. D. Beadell Investment Counsel Inc.

A. D. Beadell Investment Counsel Inc. lowered its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 0.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,808 shares of the medical instruments supplier’s stock after selling 57 shares during the period. Becton Dickinson and accounts for 2.6% of A. D. Beadell Investment Counsel Inc.’s investment portfolio, making the stock its 8th largest holding. A. D. Beadell Investment Counsel Inc.’s holdings in Becton Dickinson and were worth $2,986,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Pegasus Partners Ltd. acquired a new stake in shares of Becton Dickinson and in the 3rd quarter worth $2,355,000. Cedar Brook Financial Partners LLC lifted its stake in shares of Becton Dickinson and by 7.8% in the 3rd quarter. Cedar Brook Financial Partners LLC now owns 903 shares of the medical instruments supplier’s stock worth $228,000 after acquiring an additional 65 shares during the period. S. R. Schill & Associates lifted its stake in shares of Becton Dickinson and by 29.2% in the 3rd quarter. S. R. Schill & Associates now owns 1,373 shares of the medical instruments supplier’s stock worth $347,000 after acquiring an additional 310 shares during the period. Rhumbline Advisers lifted its stake in shares of Becton Dickinson and by 1.8% in the 3rd quarter. Rhumbline Advisers now owns 418,664 shares of the medical instruments supplier’s stock worth $105,905,000 after acquiring an additional 7,274 shares during the period. Finally, AdvisorNet Financial Inc lifted its stake in shares of Becton Dickinson and by 12.0% in the 3rd quarter. AdvisorNet Financial Inc now owns 1,867 shares of the medical instruments supplier’s stock worth $472,000 after acquiring an additional 200 shares during the period. Hedge funds and other institutional investors own 84.26% of the company’s stock.

Shares of NYSE BDX opened at $245.90 on Friday. The company has a quick ratio of 0.67, a current ratio of 1.09 and a debt-to-equity ratio of 0.84. Becton Dickinson and Co has a 52 week low of $208.62 and a 52 week high of $264.74. The firm has a 50-day moving average price of $254.31 and a 200 day moving average price of $246.24. The stock has a market capitalization of $67.56 billion, a price-to-earnings ratio of 22.33, a price-to-earnings-growth ratio of 1.60 and a beta of 1.12.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Tuesday, August 6th. The medical instruments supplier reported $3.08 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.05 by $0.03. Becton Dickinson and had a net margin of 5.02% and a return on equity of 14.78%. The firm had revenue of $4.35 billion during the quarter, compared to analysts’ expectations of $4.37 billion. During the same quarter last year, the business earned $2.91 earnings per share. The business’s revenue for the quarter was up 1.7% compared to the same quarter last year. Equities research analysts expect that Becton Dickinson and Co will post 11.68 EPS for the current fiscal year.

In other Becton Dickinson and news, Director Claire Fraser sold 1,429 shares of the firm’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $243.26, for a total transaction of $347,618.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Roland Goette sold 1,717 shares of the firm’s stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $249.88, for a total transaction of $429,043.96. Following the transaction, the executive vice president now owns 19,966 shares of the company’s stock, valued at $4,989,104.08. The disclosure for this sale can be found here. Insiders sold 37,249 shares of company stock valued at $9,616,803 in the last quarter. Company insiders own 0.12% of the company’s stock.

BDX has been the subject of several recent analyst reports. Raymond James raised their target price on shares of Becton Dickinson and from $265.00 to $288.00 and gave the stock a “strong-buy” rating in a research note on Friday, June 28th. Morgan Stanley raised their target price on shares of Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 16th. Piper Jaffray Companies reduced their target price on shares of Becton Dickinson and from $267.00 to $266.00 and set an “overweight” rating for the company in a research note on Tuesday, August 6th. ValuEngine cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, Wells Fargo & Co raised their target price on shares of Becton Dickinson and from $270.00 to $290.00 and gave the stock an “outperform” rating in a research note on Friday, September 6th. Five research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $266.55.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: Institutional Investors

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.